KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Molecular Oncology · 2026-11 · 20 (11) · 2896-2917
DOI: 10.1002/1878-0261.70238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 23.03.2026. Verfasst von Jennie N Jeyapalan und 16 weiteren Autor:innen. Beteiligte Einrichtung: School of Veterinary Medicine and Sciences, University of Nottingham, Sutton Bonington, UK. Hauptthemen laut MEDLINE: Histone Demethylases, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Prostate Cancer UK, Biotechnology and Biological Sciences Research Council.
Abstract (Originalsprache)
Treatment resistance has become a major challenge in cancer research, particularly for patients with advanced castration resistant prostate cancer (CRPC) where no curative therapies are available. Epigenetic alterations play a significant role in cancer progression. In prostate cancer (PCa), where androgen receptor (AR) is the primary oncogenic driver, epigenetic coregulators, specifically lysine demethylases (KDMs), have previously been identified as factors that alter the transcriptome as cancer cells acquire resistance. KDM7A has been identified as a cancer‐promoting factor in many cancers; however, its role in PCa remains largely unexplored. This study investigates the clinical relevance of KDM7A in comparison with the well‐studied KDM1A in PCa. Using PCa cell line models, we confirm KDM7A as an AR coregulator. By exploiting commercially available pharmacological inhibitors, we demonstrate that in AR‐positive CRPC cell lines, combinatory inhibition of KDM1A and KDM7A leads to a loss of AR and the AR‐driven transcriptome, which in turn attenuates cancer‐promoting cell phenotypes. These findings highlight the potential of combination‐targeted therapies in tackling advanced prostate cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Veterinary Medicine and Sciences, University of Nottingham, Sutton Bonington, UK.
- Biodiscovery Institute, University of Nottingham, UK.
- COMPATH, Institute of Animal Pathology, University of Bern, Switzerland.
- Department of Oncology, University Hospital Ibadan, Nigeria.
- Department of Molecular Biology, Umeå University, Sweden.
- Department of Biomedical Sciences, Malmö Universitet, Sweden.
ORCID-Profile: Jennie N Jeyapalan, Nigel P Mongan
Förderung
- Prostate Cancer UK
- Biotechnology and Biological Sciences Research Council
Zitieren
APA
Jeyapalan, J. N., Metzler, V. M., de Brot, S., Woodcock, C. L., Harris, A. E., Lothion-Roy, J., Nilsson, E. M., Ntekim, A., Toss, M. S., Persson, J. L., Khani, F., Robinson, B. D., Gudas, L. J., Rakha, E., Heery, D. M., Rutland, C. S., & Mongan, N. P. (2026). KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer. Molecular Oncology, 20(11), 2896-2917. https://doi.org/10.1002/1878-0261.70238
Vancouver
Jeyapalan JN, Metzler VM, de Brot S, Woodcock CL, Harris AE, Lothion-Roy J, et al. KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer. Molecular Oncology. 2026;20(11):2896-2917. doi:10.1002/1878-0261.70238
BibTeX
@article{Jeyapalan2026,
author = {Jeyapalan, Jennie N and Metzler, Veronika M and de Brot, Simone and Woodcock, Corinne L and Harris, Anna E and Lothion-Roy, Jennifer and Nilsson, Emeli M and Ntekim, Atara and Toss, Michael S and Persson, Jenny L and Khani, Francesca and Robinson, Brian D and Gudas, Lorraine J and Rakha, Emad and Heery, David M and Rutland, Catrin S and Mongan, Nigel P},
title = {KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer},
journal = {Molecular Oncology},
year = {2026},
volume = {20},
number = {11},
pages = {2896--2917},
doi = {10.1002/1878-0261.70238}
}
EUVIMED